Vir Biotechnology, Inc. 8-K

What Happened

• Vir Biotechnology, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release dated May 6, 2026. The company furnished that press release as Exhibit 99.1 to an 8-K filed the same day (Item 2.02, Results of Operations and Financial Condition). The 8-K was signed by Jason O’Byrne, Executive VP and Chief Financial Officer.

Key Details

• Filing date: May 6, 2026; applicable quarter: ended March 31, 2026.
• Item reported: 2.02 — Results of Operations and Financial Condition; press release furnished as Exhibit 99.1 and incorporated by reference.
• Additional exhibit: Inline XBRL cover page (Exhibit 104) included in the filing.
• 8-K executed by Jason O’Byrne, EVP & CFO.

Why It Matters

• This filing notifies investors that Vir has released its latest quarterly results; the press release (Exhibit 99.1) will contain the specific numbers — revenue, net income/loss, cash position, and any management commentary or guidance changes.
• Investors should review the furnished press release and related filings (e.g., the upcoming Form 10-Q) for the detailed financial metrics and any updates affecting valuation, cash runway, or program progress. The 8-K itself confirms the release but does not present the full financial statements within the form.